Mosanna Therapeutics eyes clinical trials after seed extension

Founded in 2022, Mosanna has quickly established a specialist core team and a reputable advisory Board and is on-track to submit an IND by the end of 2023. The company will utilize the funds for manufacturing and regulatory activities in preparation for a multi-study clinical development program. The clinical trial will most probably launched in Q1 2024.

“We are extremely pleased with the data we are seeing in the lab and the technical performance of the product and this additional financing is testament to the potential the team sees for this to translate into significant clinical benefit for Sleep Apnea patients” said Jonathan Talbot, Co-Founder and CEO of Mosanna.

Commenting on the investment, Supermoon Co-Founder Mike Masterson said: “Sleep Apnea therapy has historically been limited to a small handful of products that many patients find uncomfortable and undesirable. Mosanna’s unique approach will expand the range of Sleep Apnea treatment options and provide therapy in a familiar, user-friendly modality.”

“This is a new frontier for Sleep Apnea and we are absolutely confident Mosanna will successfully develop MOS-118 and redefine standard of care.” Said Laura Pedroza, Investment Manager at HTGF. ”We are incredibly excited for Mosanna’s truly novel therapeutic approach to enter the clinics early in 2024.”

Mosanna Therapeutics was co-founded by Forty51 Ventures, a Biotech Venture Capital fund focused on company formation in Biotech and its CEO, Jonathan Talbot. Forty51 Ventures led the Seed Financing.

Widespread disorder

Metabolic Obstructive Sleep Apnea (MOSA) is characterized by obstruction of the upper airway during sleep that occurs when the muscles that support the soft tissues in the throat temporarily relax. Breathing is impaired or completely prevented causing blood oxygen levels to drop below the normal range. Low oxygen levels increase cardiac load and stress the nervous system which if left untreated increases significantly the risk for cardiovascular mortality. MOSA can also result in excessive daytime sleepiness and memory or concentration problems. Hundreds of millions of people around the globe are affected by MOSA.

(Press release / SK)